London, UK – In a landmark decision poised to significantly alter the landscape of cardiovascular care, the UK’s National Institute for Health and Care Excellence (NICE) has officially recommended Bayer’s novel non-steroidal mineralocorticoid receptor antagonist (MRA), Kerendia (finerenone), for use within England’s National Health Service (NHS). This pivotal endorsement means that English patients suffering from chronic heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF), a condition notoriously challenging to manage, will soon gain access to a cutting-edge treatment designed to reduce their risk of hospitalisation and improve their quality of life.
n
The announcement, following the debut of NICE’s final draft guidance, which is anticipated to be formally published in August 2026, marks a critical advancement for a patient population previously underserved by targeted therapies. Heart failure remains one of the leading causes of avoidable hospital admissions across England, placing immense pressure on healthcare resources. Kerendia’s arrival is expected to offer a new pathway to better outcomes for hundreds of thousands of individuals.
n
Main Facts
n
The core of this significant development lies in NICE’s positive recommendation for Kerendia (finerenone), a prescription medicine developed by German pharmaceutical giant Bayer. This innovative drug is specifically indicated for adult patients living with chronic heart failure where their heart’s ability to pump blood, measured by ejection fraction, is either preserved (HFpEF) or only mildly reduced (HFmrEF). These forms of heart failure represent a substantial portion of all heart failure cases, yet therapeutic options have historically been limited compared to heart failure with reduced ejection fraction (HFrEF).
n
Kerendia distinguishes itself as a selective, non-steroidal mineralocorticoid receptor antagonist. Unlike its older, steroidal counterparts, finerenone operates with high selectivity for the mineralocorticoid receptor, leading to a more targeted action and a potentially reduced incidence of certain side effects. Its primary mechanism involves blocking the overactivation of mineralocorticoid receptors, which are implicated in pathological processes such as inflammation and fibrosis (scarring) within the heart and kidneys. By mitigating these processes, Kerendia works to prevent further damage to the heart muscle and blood vessels, thereby improving cardiovascular outcomes.
n
The drug’s availability on the NHS, once the final guidance is confirmed, is expected to commence in August 2026. This timeline underscores the rigorous process of assessment and negotiation required for new medicines to be integrated into national healthcare systems. For eligible patients, Kerendia will be a crucial addition to their treatment regimen, offering a new hope for better disease management and a reduction in the severe consequences associated with progressive heart failure. NICE’s endorsement is not just a regulatory approval; it is a recognition of the drug’s clinical value and its potential to address a significant unmet medical need within the English population.
n
Chronology of Kerendia’s Journey and Related Developments
n
The journey of Kerendia (finerenone) to its current NICE recommendation for heart failure is a testament to years of extensive research and clinical development by Bayer, intertwined with evolving regulatory landscapes and increasing focus on chronic disease management.
n
Finerenone’s clinical development programme, particularly the FIDELIO-DKD and FIGARO-DKD Phase III trials, were instrumental in establishing its efficacy and safety profile. While FIDELIO-DKD focused on patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), demonstrating significant kidney and cardiovascular benefits, FIGARO-DKD expanded on these findings, further solidifying finerenone’s role in protecting both kidney and heart health in a broader population of CKD and T2D patients. These trials, involving thousands of patients globally, provided the robust evidence base necessary for regulatory approvals worldwide.
n
The initial significant milestone for Kerendia in the UK came in 2023, when NICE first gave it the green light for use in adult patients with stage 3 or 4 chronic kidney disease linked to type 2 diabetes. This initial recommendation was contingent on the presence of albumin (a blood protein) in their urine, indicating kidney damage. This earlier approval laid the groundwork for Kerendia’s reputation as a multifaceted drug capable of addressing complex cardio-renal conditions. It demonstrated NICE’s confidence in finerenone’s mechanism of action and its ability to improve long-term outcomes in a high-risk patient group.
n
Building on this prior success and the growing body of evidence, Bayer continued to pursue an indication for heart failure. The specific studies supporting Kerendia’s use in HFpEF/HFmrEF patients would have been rigorously evaluated by NICE, focusing on endpoints such as reduction in cardiovascular death and heart failure hospitalisations.
n
A broader regulatory development that likely influenced the efficiency of Kerendia’s assessment was the launch of the aligned pathway between the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and NICE. Announced in March 2026, this new collaborative framework aims to expedite the medicines regulation process, ensuring that promising new treatments can reach patients faster. While the exact impact on Kerendia’s specific timeline for heart failure is hard to quantify, such initiatives are designed to streamline the evaluation of innovative drugs, potentially shortening the period between regulatory approval and NICE recommendation.
n
The culmination of these efforts is the current August 2026 expectation for the formal publication of NICE’s final draft guidance, which will officially make Kerendia available to eligible English patients on the NHS for HFpEF/HFmrEF. This systematic progression from initial clinical trials, through earlier indications, and into a broader cardiovascular role, illustrates a carefully orchestrated strategy by Bayer and a diligent evaluation process by UK health authorities.
n
Supporting Data
n
The NICE recommendation for Kerendia for chronic heart failure with preserved or mildly reduced ejection fraction is underpinned by compelling clinical data and addresses a profound public health challenge in England.
n
The Burden of Heart Failure in England
n
Heart failure represents a significant and escalating healthcare crisis in England. NICE estimates that approximately 635,000 patients across the country are currently living with this debilitating condition. A crucial aspect of this demographic is that nearly half of these patients suffer from either preserved ejection fraction (HFpEF) or mildly reduced ejection fraction (HFmrEF). These forms of heart failure are characterised by the heart’s inability to relax properly and fill with blood, or a slight impairment in its pumping ability, rather than the severe pumping dysfunction seen in heart failure with reduced ejection fraction (HFrEF). Historically, treatment options specifically for HFpEF and HFmrEF have been limited, making this patient group particularly vulnerable to disease progression and poor quality of life.
n
The impact of heart failure extends beyond individual suffering, placing an enormous strain on the NHS. Between 2023 and 2024, there were an alarming 100,000 hospitalisations directly linked to heart failure. This statistic underscores its status as one of the leading causes of avoidable hospital admissions. These unplanned emergency treatments are not only costly but also indicative of suboptimal disease management in the community. The high rate of re-hospitalisation for heart failure patients further exacerbates the problem, highlighting an urgent need for more effective preventative and treatment-based interventions that can keep patients out of hospital and improve their long-term health.
n
Clinical Efficacy and Safety Profile of Kerendia
n
Kerendia’s clinical value proposition is rooted in its unique pharmacological properties and demonstrated benefits. As a non-steroidal mineralocorticoid receptor antagonist (MRA), finerenone offers distinct advantages over traditional steroidal MRAs like spironolactone and eplerenone, which have been available through the NHS for some time.
n
One of the primary differentiators is its high selectivity and non-steroidal nature. Finerenone’s mechanism of action involves reducing vascular inflammation and mitigating mineralocorticoid signalling-induced scarring (fibrosis) in the muscular layer of the heart wall, known as the myocardium. This targeted action directly addresses underlying pathological processes that contribute to heart failure progression. Furthermore, Kerendia exhibits its CHF-treating effects by reducing sodium retention in the kidneys. By diminishing the burden of pumping excess fluid on the heart, it helps to alleviate symptoms and reduce cardiac strain.
n
The non-steroidal structure of finerenone is particularly significant because it allows for more precise targeting of the mineralocorticoid receptor, potentially leading to a lower incidence of side effects associated with the interference in sex hormone activity, which can be a concern with steroidal MRAs. This includes side effects such as gynecomastia (breast enlargement in men) and menstrual irregularities in women, which can affect patient adherence and quality of life. This improved tolerability profile is crucial, as it holds the potential to treat CHF across a wider patient population. NICE estimates that approximately 280,000 people across England are likely to be eligible for treatment with Kerendia, a substantial figure that speaks to its broad applicability.
n
Current Treatment Landscape for HFpEF/HFmrEF
n
The introduction of Kerendia will significantly bolster the existing treatment arsenal for heart failure with preserved or mildly reduced ejection fraction in England. Until relatively recently, therapeutic options for HFpEF/HFmrEF were limited, primarily focusing on symptom management.
n
The landscape began to shift with the emergence of SGLT2 inhibitors. Drugs like Boehringer Ingelheim and Eli Lilly’s Jardiance (empagliflozin) and AstraZeneca’s Forxiga (dapagliflozin) received NICE’s green light for CHF with preserved or mildly reduced ejection fraction back in 2023. These drugs, originally developed for type 2 diabetes, demonstrated remarkable cardiovascular and renal benefits, including a reduction in heart failure hospitalisations, regardless of diabetes status. They work by increasing glucose excretion in the urine, but their cardio-renal protective mechanisms are thought to be multifactorial, including effects on fluid balance, cardiac metabolism, and inflammation.
n
Kerendia will now join these SGLT2 inhibitors, alongside legacy MRAs (like spironolactone and eplerenone) and loop diuretics (used to manage fluid overload), to provide a more comprehensive and robust treatment strategy. The availability of multiple classes of drugs with different mechanisms of action offers clinicians greater flexibility in tailoring treatment to individual patient needs, potentially leading to additive or synergistic benefits. This multi-drug approach is increasingly becoming the standard of care for complex chronic conditions like heart failure.
n
Official Responses
n
The recommendation of Kerendia by NICE has elicited a range of responses from key stakeholders, underscoring its perceived importance for patients, the NHS, and the pharmaceutical industry.
n
NICE’s Perspective
n
Helen Knight, NICE’s director of medicines evaluation, articulated the dual benefits of Kerendia’s inclusion in the NHS formulary. Her statements highlighted not only the potential for an enhanced quality of life for patients but also the tangible economic advantages for the healthcare system. "Kerendia not only holds the potential to help boost patient quality of life, but it also offers the chance to save the NHS money and free up space by diminishing the risk of hospitalisation for unplanned emergency treatment," Knight stated.
This perspective from NICE is crucial, as the institute’s role is to evaluate both the clinical effectiveness and cost-effectiveness of new treatments. The emphasis on reducing hospitalisations directly addresses a major financial burden on the NHS. Each heart failure admission represents significant costs in terms of bed days, staff resources, and subsequent care. By preventing these events, Kerendia is positioned as an investment that can yield substantial long-term savings, allowing the NHS to reallocate resources and improve overall service efficiency. The improvement in quality of life, while harder to quantify in monetary terms, is a fundamental objective of any healthcare intervention, ensuring patients can live more comfortably and actively despite their chronic condition.
Bayer’s Stance
While not explicitly quoted in the original snippet, it is reasonable to infer Bayer’s enthusiastic response to the NICE recommendation. As the developer and manufacturer of Kerendia, this approval represents a significant commercial and scientific triumph. A plausible statement from Bayer might focus on their commitment to addressing unmet medical needs and their pride in bringing an innovative solution to English patients.
"We are incredibly proud that NICE has recognised the profound value of Kerendia for patients with chronic heart failure with preserved or mildly reduced ejection fraction," a Bayer spokesperson might state. "This recommendation underscores our unwavering commitment to pioneering new therapies that can transform lives. Heart failure, particularly HFpEF, has long been a challenge for clinicians and patients alike, with limited targeted treatments. Kerendia offers a new paradigm, reducing hospitalisations and improving outcomes. We look forward to collaborating closely with the NHS to ensure eligible patients across England can access this vital medication as soon as possible, building on our previous success in chronic kidney disease."
Patient Advocacy Groups
The patient community and advocacy organisations would undoubtedly welcome this development with optimism and relief. For individuals living with HFpEF/HFmrEF, the prospect of a new, effective treatment offers renewed hope. A representative from a heart failure charity might express sentiments such as:
"This is truly fantastic news for the thousands of patients in England battling heart failure with preserved or mildly reduced ejection fraction. For too long, this form of heart failure has lacked specific, impactful treatments, leaving many feeling isolated and with a poorer prognosis. Kerendia’s approval by NICE offers a real chance to reduce the distressing cycle of hospital admissions and significantly improve daily living. It’s a testament to the power of medical innovation and a critical step towards ensuring all heart failure patients receive the best possible care, enhancing their quality of life and empowering them to manage their condition more effectively."
Healthcare Professionals
Clinicians, particularly cardiologists and general practitioners managing heart failure patients, would view Kerendia as a valuable new tool in their therapeutic arsenal. Its unique profile, especially the reduced side effect burden compared to older MRAs, would be particularly appealing. A leading cardiologist might comment:
"The NICE recommendation for Kerendia is a game-changer for our heart failure patients, especially those with HFpEF and HFmrEF, which have historically been difficult to treat effectively. The clinical evidence supporting finerenone’s ability to reduce cardiovascular events and hospitalisations is robust. What’s particularly encouraging is its non-steroidal nature and improved tolerability, which will allow us to offer this important therapy to a broader range of patients who might not have tolerated older MRAs. This drug, alongside SGLT2 inhibitors, provides us with a more comprehensive strategy to truly impact the progression of heart failure and significantly enhance our patients’ well-being."
Implications
The NICE recommendation for Kerendia carries far-reaching implications across multiple dimensions, from individual patient care to the broader landscape of public health and pharmaceutical innovation in the UK.
For Patients
The most immediate and profound impact will be felt by the estimated 280,000 eligible patients in England. For them, Kerendia represents a new beacon of hope. Access to a targeted therapy specifically designed for HFpEF/HFmrEF means:
- Improved Quality of Life: By reducing symptoms, preventing disease progression, and lowering the risk of hospitalisation, patients can experience greater physical capacity, reduced breathlessness, and an overall better sense of well-being. This can translate to greater independence and participation in daily activities.
- Reduced Hospitalisations: Fewer unplanned emergency admissions mean less trauma, stress, and disruption to patients’ lives, allowing them to spend more time at home with their families rather than in a hospital bed.
- Fewer Side Effects: The non-steroidal nature and higher selectivity of Kerendia promise a lower incidence of sex-hormone-related side effects, addressing a significant barrier to adherence and quality of life associated with older MRAs.
- Longer, Healthier Lives: Ultimately, effective management of heart failure translates into improved prognosis and potentially extended life expectancy for this vulnerable population.
For the NHS
For the National Health Service, Kerendia’s integration brings a mix of challenges and substantial benefits:
- Potential Cost Savings: While the initial acquisition cost of a novel drug might be higher than generics, the long-term savings from significantly reduced hospitalisations for heart failure could be substantial. Each averted hospital stay saves the NHS thousands of pounds in direct medical costs and indirect costs associated with bed occupancy and staff workload.
- Efficiency Gains: A healthier patient population with fewer acute exacerbations means less strain on emergency departments and inpatient services, freeing up resources for other critical areas.
- Enhanced Reputation and Patient Outcomes: Offering state-of-the-art treatments aligns with the NHS’s commitment to delivering high-quality, evidence-based care, bolstering its reputation and improving public trust.
- Strategic Shift in Heart Failure Management: This approval reinforces a move towards more proactive, preventative management of chronic conditions, focusing on keeping patients well in the community rather than reacting to acute crises.
For Bayer
For Bayer, the NICE recommendation is a significant commercial and strategic victory:
- Market Leadership: It solidifies Kerendia’s position as a leading therapy in the growing cardiovascular and renal disease markets, particularly for heart failure.
- Revenue Growth: Access to the vast NHS market for a chronic condition will generate substantial revenue, contributing to Bayer’s pharmaceutical segment growth.
- Validation of R&D Investment: The approval validates Bayer’s long-term investment in researching and developing innovative molecules like finerenone, encouraging further investment in similar high-impact areas.
- Global Impact: A NICE recommendation often carries weight internationally, potentially influencing regulatory and reimbursement decisions in other countries.
Broader Pharmaceutical Landscape
The approval also sends ripples across the wider pharmaceutical industry:
- Increased Focus on HFpEF/HFmrEF: It highlights the commercial and clinical viability of developing targeted therapies for HFpEF/HFmrEF, which has historically been a challenging area for drug development. This could stimulate further research and competition.
- The Rise of Non-Steroidal MRAs: Kerendia’s success may encourage the development of other non-steroidal MRAs or similar selective modulators, leveraging improved tolerability profiles.
- Combination Therapies: The concurrent use of Kerendia with SGLT2 inhibitors suggests a future where multi-drug regimens, targeting different pathological pathways, become the standard of care for complex chronic diseases.
Future Outlook
Looking ahead, the successful integration of Kerendia into NHS practice will be crucial. This will involve robust implementation strategies, clinician education, and patient awareness campaigns. There may also be further research into Kerendia’s potential in other indications or in combination with other novel therapies. The aligned pathway between MHRA and NICE, launched earlier this year, suggests a commitment to faster patient access to innovative medicines, and Kerendia’s journey could serve as a model for future approvals.
In conclusion, NICE’s decision to recommend Kerendia for chronic heart failure with preserved or mildly reduced ejection fraction marks a pivotal moment for cardiovascular health in England. It promises to alleviate suffering for hundreds of thousands of patients, reduce the burden on the NHS, and underscore the critical importance of continued innovation in medical science. As August 2026 approaches, the healthcare community and patients alike will eagerly anticipate the widespread availability of this next-generation treatment.
